<DOC>
	<DOC>NCT02033889</DOC>
	<brief_summary>This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).</brief_title>
	<detailed_description>The trial includes a 13-15 week run-in period prior to randomization, and a 26-week, double-blind, placebo-controlled treatment period (Phase A) followed by a 78-week double-blind, extension period (Phase B).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis of T2DM in accordance to American Diabetes Association guidelines Participants must be receiving metformin monotherapy for less than 8 weeks prior to study participation or require change in their diabetes regimen to remain eligible to participate in the trial (including discontinuing antihyperglycemic agent [AHA] therapy) and must have a hemoglobin A1c of 7.0 to 10.5% (5391 mmol/mol) after at least 8 weeks on a regimen of metformin monotherapy History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class IIIIV heart failure within 3 months of study participation A clinically significant electrocardiogram abnormality A history of malignancy â‰¤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer A known hypersensitivity or intolerance to any sodiumglucose cotransporter 2 (SGLT2) inhibitor or glimepiride On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial Pregnant or breastfeeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>